Artia Global Partners’s Verona Pharma VRNA Stock Holding History

Artia Global Partners’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-379,004	Closed	-$40.4M	–	72
2025 Q3	$40.4M	Sell	379,004 -545,200	-59%	-$56.9M	6.41%	5
2025 Q2	$87.4M	Buy	924,204 +385,716	+72%	+$28.6M	21.03%	1
2025 Q1	$34.2M	Buy	538,488 +283,170	+111%	+$16.9M	8.65%	4
2024 Q4	$11.9M	Buy	255,318 +106,728	+72%	+$4.01M	4.24%	12
2024 Q3	$4.27M	Buy	148,590 +17,800	+14%	+$438K	1.17%	17
2024 Q2	$1.89M	Hold	130,790	–	–	0.37%	29
2024 Q1	$2.1M	Hold	130,790	–	–	0.42%	26
2023 Q4	$2.6M	Buy	+130,790	New	+$1.93M	0.76%	16
2023 Q2	–	Sell	-90,451	Closed	-$1.82M	–	43
2023 Q1	$1.82M	Buy	90,451 +50,500	+126%	+$1.09M	0.67%	23
2022 Q4	$1.04M	Buy	+39,951	New	+$532K	0.4%	22

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Artia Global Partners's VRNA Position: Q4 2025 in Review

Artia Global Partners sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 379,004 shares — an estimated $40.4M sold.

Artia Global Partners first reported a position in VRNA in Q4 2022 and held it in 10 quarters. The position peaked at $87.4M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Artia Global Partners reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Artia Global Partners sold 379,004 Verona Pharma shares in Q4 2025, an estimated $40.4M.
Artia Global Partners first reported a position in Verona Pharma in Q4 2022 and held it in 10 quarters.
Artia Global Partners's Verona Pharma position peaked at $87.4M in Q2 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.